Literature DB >> 2054258

Clinical studies with TNF.

T Taguchi1, Y Sohmura.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 2054258     DOI： 10.1007/bf02172090

Source DB:  PubMed          Journal:  Biotherapy        ISSN： 0921-299X


× No keyword cloud information.
  4 in total

1.  Dissociation of TNF-alpha cytotoxic and proinflammatory activities by p55 receptor- and p75 receptor-selective TNF-alpha mutants.

Authors:  J A Barbara; W B Smith; J R Gamble; X Van Ostade; P Vandenabeele; J Tavernier; W Fiers; M A Vadas; A F Lopez
Journal:  EMBO J       Date:  1994-02-15       Impact factor: 11.598

2.  A human tumor necrosis factor (TNF) alpha mutant that binds exclusively to the p55 TNF receptor produces toxicity in the baboon.

Authors:  K J Van Zee; S A Stackpole; W J Montegut; M A Rogy; S E Calvano; K C Hsu; M Chao; C L Meschter; H Loetscher; D Stüber
Journal:  J Exp Med       Date:  1994-04-01       Impact factor: 14.307

Review 3.  Intravenous ascorbic acid as an adjuvant to interleukin-2 immunotherapy.

Authors:  Samuel C Wagner; Boris Markosian; Naseem Ajili; Brandon R Dolan; Andy J Kim; Doru T Alexandrescu; Constantin A Dasanu; Boris Minev; James Koropatnick; Francesco M Marincola; Neil H Riordan
Journal:  J Transl Med       Date:  2014-05-13       Impact factor: 5.531

4.  Dipyridamole combined with tumor necrosis factor-alpha enhances inhibition of proliferation in human tumor cell lines.

Authors:  N Suzuki; S Sekiya; I Sugano; T Kojima; H Yamamori; Y Takakubo
Journal:  Jpn J Cancer Res       Date:  1995-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.